Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -49.93% is 13% above its 5-year average of -57.07%, around the middle of its 5-year range (-117.31%–-18.14%).
47.66% above its 12-month average of -95.40%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -15.78%.
RETURN ON ASSETS (ROA)
-49.93%
RETURN ON ASSETS (ROA) AVG TTM
-95.40%
RETURN ON ASSETS (ROA) AVG 3Y
-72.70%
RETURN ON ASSETS (ROA) AVG 5Y
-57.07%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+47.66%
CURRENT VS 3Y AVG
+31.33%
CURRENT VS 5Y AVG
+12.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-54.75%
vs the sector median at left
Spruce Biosciences, Inc.
Market Cap
$117.76M
Return on Assets (ROA)
-49.93%
TTM Avg
-95.40%
3Y Avg
-72.70%
5Y Avg
-57.07%
Market Cap
$118.59M
Return on Assets (ROA)
-110.24%
TTM Avg
-77.16%
3Y Avg
-67.85%
5Y Avg
-53.38%
Market Cap
$116.76M
Return on Assets (ROA)
-19.30%
TTM Avg
-19.59%
3Y Avg
-15.38%
5Y Avg
-15.18%
Market Cap
$118.83M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$119.84M
Return on Assets (ROA)
-31.33%
TTM Avg
-56.73%
3Y Avg
-59.49%
5Y Avg
-64.55%
Market Cap
$115.67M
Return on Assets (ROA)
-31.75%
TTM Avg
-34.00%
3Y Avg
-32.33%
5Y Avg
-29.29%
Market Cap
$120.41M
Return on Assets (ROA)
-26.48%
TTM Avg
-24.24%
3Y Avg
-21.83%
5Y Avg
-17.99%
Market Cap
$120.58M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
Market Cap
$114.46M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spruce Biosciences, Inc. (SPRB) | $117.76M | -49.93% | -95.40% | -72.70% | -57.07% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | -110.24% | -77.16% | -67.85% | -53.38% |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -19.30% | -19.59% | -15.38% | -15.18% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | -53.26% | -24.98% | -43.10% | -143.56% |
| Cibus, Inc. (CBUS)vs › | $119.84M | -31.33% | -56.73% | -59.49% | -64.55% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | -31.75% | -34.00% | -32.33% | -29.29% |
| Seer, Inc. (SEER)vs › | $120.41M | -26.48% | -24.24% | -21.83% | -17.99% |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | -1.70% | -35.34% | -51.03% | -36.99% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -134.18% | -145.83% | -164.39% | -180.40% |
| Genelux Corporation (GNLX)vs › | $113.89M | -128.96% | -127.49% | -112.64% | -129.28% |
ROA
-49.9%
ROE
-61.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -73.49% |
| 2024-12-31 | -117.31% |
| 2023-12-31 | -46.10% |
| 2022-12-31 | -53.92% |
| 2021-12-31 | -33.44% |
| 2020-12-31 | -18.14% |
| 2019-12-31 | -282.12% |
| 2018-12-31 | -206.45% |
